Literature DB >> 2472114

Inhibition of HIV replication by liposomal encapsulated amphotericin B.

D R Pontani1, D Sun, J W Brown, S I Shahied, O J Plescia, C P Schaffner, G Lopez-Berestein, P S Sarin.   

Abstract

This report shows the potential of using a liposomal encapsulated preparation of amphotericin B (a polyene macrolide antibiotic) for the in vitro inhibition of HIV. There was no significant difference between the effective doses of the free form of drug when compared to the liposomal encapsulated preparation in inhibiting the growth of HIV. Virus expression was suppressed at a concentration of 5-10 micrograms/ml of the drugs. The liposomal preparation showed greatly reduced cytotoxicity in experiments using cultures of murine leukocytes. These results show the potential usefulness of liposomal encapsulated drugs in the treatment of patients with AIDS or AIDS related complex.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2472114     DOI： 10.1016/0166-3542(89)90023-5

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


  8 in total

1.  Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities.

Authors:  M Ramaswamy; K D Peteherych; A L Kennedy; K M Wasan
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

2.  Species differences in the proportion of plasma lipoprotein lipid carried by high-density lipoproteins influence the distribution of free and liposomal nystatin in human, dog, and rat plasma.

Authors:  M Ramaswamy; T L Wallace; P A Cossum; K M Wasan
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

3.  Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories.

Authors:  F B Hollinger; J W Bremer; L E Myers; J W Gold; L McQuay
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

4.  Effect of fasting on temporal variation in the nephrotoxicity of amphotericin B in rats.

Authors:  M LeBrun; L Grenier; M G Bergeron; L Thibault; G Labrecque; D Beauchamp
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

5.  Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies.

Authors:  K M Wasan; A L Kennedy; S M Cassidy; M Ramaswamy; L Holtorf; J W Chou; P H Pritchard
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

6.  Differences in the lipoprotein distribution of free and liposome-associated all-trans-retinoic acid in human, dog, and rat plasma are due to variations in lipoprotein lipid and protein content.

Authors:  K M Wasan; M Ramaswamy; S P Ng; W Wong; S C Parrott; J O Ojwang; T Wallace; P A Cossum
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

7.  Amphotericin B Inhibits Enterovirus 71 Replication by Impeding Viral Entry.

Authors:  Fengwen Xu; Xiaoxiao Zhao; Siqi Hu; Jian Li; Lijuan Yin; Shan Mei; Tingting Liu; Ying Wang; Lili Ren; Shan Cen; Zhendong Zhao; Jianwei Wang; Qi Jin; Chen Liang; Bin Ai; Fei Guo
Journal:  Sci Rep       Date:  2016-09-09       Impact factor: 4.379

Review 8.  Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?

Authors:  Aline Raquel Voltan; Guillermo Quindós; Kaila P Medina Alarcón; Ana Marisa Fusco-Almeida; Maria José Soares Mendes-Giannini; Marlus Chorilli
Journal:  Int J Nanomedicine       Date:  2016-08-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.